Aligos CEO Secures Decade‑Long Option Stakes, Betting on a 2035 Breakthrough as Stock Slides Below $7【】
Aligos’ new long‑term stock‑option grants signal executive confidence in the biotech’s future, hinting at potential upside as clinical milestones loom.
3 minutes to read